div class=ts-pagebuttonPage 1button div class=ts-image a href=https:reader042vdocumentscoreader042viewer20220411015ed8e6576714ca7f4768c76bhtml5page1jpg target=_blank amp-img class=ts-thumb alt=Page 1: repebisupcheduperepebisupchedupearticulosactacancerolv21n2a4pdf · RESUME N El Régimen FEM Fluoruracil - Epidoxorubicina - Mitomicina fué evaluado en 19 pacientes src=https:reader042vdocumentscoreader042viewer20220411015ed8e6576714ca7f4768c76bhtml5thumbnails1jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 2button div class=ts-image a href=https:reader042vdocumentscoreader042viewer20220411015ed8e6576714ca7f4768c76bhtml5page2jpg target=_blank amp-img class=ts-thumb alt=Page 2: repebisupcheduperepebisupchedupearticulosactacancerolv21n2a4pdf · RESUME N El Régimen FEM Fluoruracil - Epidoxorubicina - Mitomicina fué evaluado en 19 pacientes src=https:reader042vdocumentscoreader042viewer20220411015ed8e6576714ca7f4768c76bhtml5thumbnails2jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 3button div class=ts-image a href=https:reader042vdocumentscoreader042viewer20220411015ed8e6576714ca7f4768c76bhtml5page3jpg target=_blank amp-img class=ts-thumb alt=Page 3: repebisupcheduperepebisupchedupearticulosactacancerolv21n2a4pdf · RESUME N El Régimen FEM Fluoruracil - Epidoxorubicina - Mitomicina fué evaluado en 19 pacientes src=https:reader042vdocumentscoreader042viewer20220411015ed8e6576714ca7f4768c76bhtml5thumbnails3jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 4button div class=ts-image a href=https:reader042vdocumentscoreader042viewer20220411015ed8e6576714ca7f4768c76bhtml5page4jpg target=_blank amp-img class=ts-thumb alt=Page 4: repebisupcheduperepebisupchedupearticulosactacancerolv21n2a4pdf · RESUME N El Régimen FEM Fluoruracil - Epidoxorubicina - Mitomicina fué evaluado en 19 pacientes src=https:reader042vdocumentscoreader042viewer20220411015ed8e6576714ca7f4768c76bhtml5thumbnails4jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 5button div class=ts-image a href=https:reader042vdocumentscoreader042viewer20220411015ed8e6576714ca7f4768c76bhtml5page5jpg target=_blank amp-img class=ts-thumb alt=Page 5: repebisupcheduperepebisupchedupearticulosactacancerolv21n2a4pdf · RESUME N El Régimen FEM Fluoruracil - Epidoxorubicina - Mitomicina fué evaluado en 19 pacientes src=https:reader042vdocumentscoreader042viewer20220411015ed8e6576714ca7f4768c76bhtml5thumbnails5jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 6button div class=ts-image a href=https:reader042vdocumentscoreader042viewer20220411015ed8e6576714ca7f4768c76bhtml5page6jpg target=_blank amp-img class=ts-thumb alt=Page 6: repebisupcheduperepebisupchedupearticulosactacancerolv21n2a4pdf · RESUME N El Régimen FEM Fluoruracil - Epidoxorubicina - Mitomicina fué evaluado en 19 pacientes src=https:reader042vdocumentscoreader042viewer20220411015ed8e6576714ca7f4768c76bhtml5thumbnails6jpg width=142 height=106 layout=responsive amp-imga divdiv